

Celadon Pharmaceuticals Plc
("Celadon", the "Group" or the "Company")
New Sales Contract with a Healthcare Company

London, 2 October 2024 - Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines, is pleased to announce it has signed a new five year sales contract with a newly established healthcare company for the supply of its medicinal cannabis product from its UK facility (the "Contract"). The Contract has minimum order quantities with a value of up to £10.5 million over the five year term, with volumes increasing materially from year one to year three under the terms of the contract. The cultivation of the products for the minimum order volume for the first supply year of the Contract shall commence no later than 12 months from signing of the contract.

Celadon entered into a strategic collaboration with Valeos Pharma A/S, a Danish EU-GMP cultivator of medicinal cannabis products in September 2024. This collaboration will allow Celadon to supply to its European customer (worth up to £26m over three years) from Valeos' Danish cultivation facility thereby reducing the administrative burden of supplying this customer from the UK and increasing the capacity of Phase 2 of Celadon's UK cultivation facility that is able to supply its UK customers.

The Contract will run for an initial term of five years, unless the parties agree otherwise.

This contract win takes the potential order book for Celadon up to c.£40.7 million when combined with the Group's £26 million European contract announced in November 2023, and the two UK contracts worth £4.2m announced in May and September 2023. The Company continues to engage in discussions with additional potential customers and is confident in securing further agreements.

James Short, Chief Executive Officer of Celadon, commented:

"We are pleased to have signed this new contract with another key healthcare partner. Our collaboration with Valeos Pharma A/S has been pivotal in increasing our ability to supply product to our pharmaceutical and healthcare customer, enabling us to begin converting our bank of Letters of Intent into signed sales agreements. This contract represents another key milestone as we continue to grow and fulfil the demand for high-quality pharmaceutical-grade medicinal cannabis.

"As demand for medicinal cannabis products continues to rise, our focus remains on delivering exceptional quality while increasing our capacity to meet this rapidly growing market."

Enquiries:

Celadon Pharmaceuticals Plc
James Short
Jonathan Turner

Via Sodali & Co

Canaccord Genuity Limited (Nominated Adviser and Broker)
Bobbie Hilliam / Andrew Potts

+44 (0)20 7523 8000

Global Investment Strategy UK Limited (Joint Broker)
James Sheehan

+44 (0)20 7048 9400

Sodali & Co
Elly Williams / Sam Austrums / Nick Johnson

+44 (0)20 7250 1446

About Celadon Pharmaceuticals Plc

Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its pharmaceutical-grade cannabis product. The Group owns an approved clinical trial using cannabis-based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics, which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder. Celadon has entered into a strategic collaboration with Valeos Pharma A/S to license certain of its intellectual property relating to facility design and operation and to assist in the supply of product to its current and potential European customers.

For further information please visit our website www.celadonpharma.com

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

CNTFSEFMFELSESS